The US Food and Drug Administration (FDA) has authorised a booster dose of the Pfizer Inc (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for those aged 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the virus, Reuters news agency reported on Thursday.
FDA Acting Commissioner Janet Woodcock stated that this change to the vaccine's emergency use authorisation will allow boosters for groups such as health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons.
An outside FDA panel of advisers voted against Pfizer's proposition that boosters were needed by everyone but said that evidence showed they were helpful to older people and those at high risk.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results